Skip to main
BNTC

BNTC Stock Forecast & Price Target

BNTC Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 80%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Benitec Biopharma Inc is positioned favorably due to its promising clinical results from the BB-301 therapeutic development for Oculopharyngeal Muscular Dystrophy (OPMD), demonstrating a significant rate of patient improvement in critical swallowing capabilities. The company's potential for productive regulatory interactions may accelerate its path to market, possibly through conditional or expedited approval avenues, enhancing the likelihood of commercial success. Additionally, the sustained improvements observed in patients indicate a high degree of efficacy and an opportunity for premium pricing based on the inherent value of the BB-301 therapy, positively impacting long-term growth prospects.

Bears say

Benitec Biopharma Inc reported a first-quarter loss of $0.21 per share, which was better than an anticipated loss of $0.41 per share, primarily attributed to an increased number of shares outstanding. The company's prospects are hindered by several key risks, including potential delays or failures in securing regulatory approval for its lead therapeutic candidate, BB-301, as well as concerns related to negative data from ongoing clinical trials and slower market adoption. Additionally, long-term financial health is jeopardized due to risks of shareholder dilution resulting from recent transactions, contributing to an overall negative outlook for the company's stock.

BNTC has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 80% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Benitec Biopharma Limited Sponsored ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Benitec Biopharma Limited Sponsored ADR (BNTC) Forecast

Analysts have given BNTC a Buy based on their latest research and market trends.

According to 5 analysts, BNTC has a Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Benitec Biopharma Limited Sponsored ADR (BNTC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.